Search

Abstract Background Obesity-associated coronary heart disease (CHD) risk is higher in women than in men with type 2 diabetes (T2DM). Resistin, an adipokine secreted by adispose tissue, may contribute to this higher risk. Aims To explore the relationships among resistin levels and common inflammatory and endothelial dysfunction markers and CHD risk in obese post-menopausal T2DM women. Methods Serum levels of resistin, hsCRP, IL-6, Soluble vascular cell adhesion molecule (sVCAM), homocysteine (tHcy), HOMA-IR and metabolic parameters were determined in a group of 132 T2DM women with and without documented CHD and in 55 non-diabetic women. Results Resistin, sVCAM, IL-6 and tHcy levels were comparable in T2DM and controls. CHD women showed higher resistin, sVCAM and tHcy levels than those without CHD, and for resistin this difference remained significant after age-adjustment (P = 0.013); conversely hsCRP were ~ 2X higher in T2DM women than in controls (P = 0.0132) without any difference according to CHD history. At univariate analysis resistin levels were significantly associated with age, waist circumference, hypertension, tHcy, hsPCR, sVCAM, IL-6, HDL-cholesterol, triglycerides and creatinine levels, but only creatinine, triglycerides, hsCRP, IL-6 and sVCAM were independently associated to resistin levels at stepwise regression analysis. Resistin levels were independently associated to CHD, increasing the risk by 1.15 times (0.986–1.344 95% CI), together with age, tHcy, LDL-C and hypertension. Conclusions Circulating resistin levels were comparable in obese/overweight T2DM and control women. In T2DM women, resistin levels correlated with markers of renal function, systemic inflammation and endothelial dysfunction and were independently associated with a higher CHD risk.

Background: Obesity-associated coronary heart disease (CHD) risk is higher in women than in men with type 2 diabetes (T2DM). Resistin, an adipokine secreted by adispose tissue, may contribute to this higher risk., Aims: To explore the relationships among resistin levels and common inflammatory and endothelial dysfunction markers and CHD risk in obese post-menopausal T2DM women., Methods: Serum levels of resistin, hsCRP, IL-6, Soluble vascular cell adhesion molecule (sVCAM), homocysteine (tHcy), HOMA-IR and metabolic parameters were determined in a group of 132 T2DM women with and without documented CHD and in 55 non-diabetic women., Results: Resistin, sVCAM, IL-6 and tHcy levels were comparable in T2DM and controls. CHD women showed higher resistin, sVCAM and tHcy levels than those without CHD, and for resistin this difference remained significant after age-adjustment (P = 0.013); conversely hsCRP were ~ 2X higher in T2DM women than in controls (P = 0.0132) without any difference according to CHD history. At univariate analysis resistin levels were significantly associated with age, waist circumference, hypertension, tHcy, hsPCR, sVCAM, IL-6, HDL-cholesterol, triglycerides and creatinine levels, but only creatinine, triglycerides, hsCRP, IL-6 and sVCAM were independently associated to resistin levels at stepwise regression analysis. Resistin levels were independently associated to CHD, increasing the risk by 1.15 times (0.986-1.344 95% CI), together with age, tHcy, LDL-C and hypertension., Conclusions: Circulating resistin levels were comparable in obese/overweight T2DM and control women. In T2DM women, resistin levels correlated with markers of renal function, systemic inflammation and endothelial dysfunction and were independently associated with a higher CHD risk., (© 2021. The Author(s).)

Magnesium is an essential bivalent cation. Its fine balance in human organism is extremely important and is involved in a wide range of functions. We need to maintain its amount in human organism within range considered as physiological. This is particularly true for elderly people, and especially for "frail" elderly people, whose systems and apparatuses are in a state of serious homeostatic precariousness. In fact, hypomagnesemia is involved in a very large range of pathological conditions (requiring multiple therapies) that could compromise elderly's autonomy. The aim of this review has been to go through the most important trials, in order to understand the direction taken by research during the last years and to detect the room for improvement in this field. We have tried to understand when magnesium content is truly physiological or pathological, and how we could prevent an inappropriately low magnesium intake in elderly people. First of all, we have remarked the absolute need of an adequate evaluation method for magnesium content in human organism. Current literature appropriately encourages the use of a synoptic assessment of magnesium serum concentration, urinary excretion, and dietary intake. We have also discussed the most important trials relating hypomagnesaemia with human pathology. Specific studies conducted on elderly patients have extensively demonstrated its decisive role in maintaining bone health, adequate glyco-metabolic compensation, a correct cardiac and vascular functional profile, and probably also a physiological psycho-cognitive profile. From the implications discussed above, therefore, it is essential to ensure physiological levels of magnesium in body, particularly in geriatric patient, itself more prone to a reduction in the level of cation. We have concluded, according to the literature, that the best way to prevent hypomagnesemia and its clinical implications in elderly subjects is represented by a proper diet (more fiber and complex carbohydrates, more vegetable proteins, less sugars and fats), which ensures an adequate supply of cation. If with diet alone (due to comorbidity or other concomitant factors) it has not been possible to guarantee suitable serum levels of cation, or in the case of a patient defined as "frail elderly", a reintegration therapy (per os) will be undertaken, after a careful analysis of renal function.